Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?

This phase 2 trial is testing whether adding a targeted therapy called fumetinib to chemotherapy before standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that has EGFR mutations and cannot be removed by surgery. Participants are randomly assigned to receive either the targeted therapy plus chemo first, or standard chemoradiation alone. The main goal is to see if the combination delays cancer progression or death, with a secondary focus on how well the tumor responds before any surgery.